Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared a post on LinkedIn:
“Radio Ligand Therapies: how precision radiation is reshaping oncology.
Tumor-targeting ligands deliver radioactive payloads systemically, irradiating cancer while trying to spare most normal tissue.
Radionuclide choice matters: β emitters enable crossfire in bulky/heterogeneous disease, α emitters do better in micrometastases.
Efficacy depends on target stability, not oncogenic addiction (PSMA, SSTR2, FAP > RTKs).
Carrier design (small molecules vs antibodies, multimerization, pre-targeting) governs penetration, retention and toxicity.
Personal dosimetry + early-line use + rational combinations (ADT, PARPi, ICB) may expand the therapeutic window.”
Title: The molecular blueprint of targeted radionuclide therapy
Authors: Irina Primac, Kevin Tabury, Alpaslan Tasdogan, Sarah Baatout, Ken Herrmann
You can read the full article in Nature Reviews – Clinical Oncology.
More posts featuring Jean-Charles Soria.